Afecta Pharmaceuticals is focused on the efficient development of late stage pharmaceutical products. Using a powerful suite of technologies, we are developing novel drugs based on new science as well as creating better pharmaceutical products that add value and enhance clinical efficacy of existing compounds.

Our basic strategy is to capitalize on the growing understanding of the molecular biology and genetics of complex disease processes and our technical expertise to create more effective therapeutics based on existing molecular platforms.

Using proprietary technologies, we identify existing compounds that are suitable for clinical development based on our assessment of mechanism of action, molecular targets affected, potential for improvements and genetic analysis of the target disease that can be exploited in clinical development.

In doing this, Afecta has assembled a portfolio of new and effective pharmaceutical products at significantly reduced overall cost that will have shortened timelines to market. We have also created novel molecular platforms that will serve as the basis for development of next generation therapeutics.